Tumour angiogenesis: vascular growth and survival
暂无分享,去创建一个
[1] A. Giatromanolaki,et al. Tumour angiogenic activity and vascular survival ability in bladder carcinoma , 2004, Journal of Clinical Pathology.
[2] D. Mavroudis,et al. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse , 2004, International journal of cancer.
[3] A. Giatromanolaki,et al. “Stromatogenesis” and Tumor Progression , 2004, International journal of surgical pathology.
[4] J. Christensen,et al. c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.
[5] A. Giatromanolaki,et al. The vascular network of tumours — what is it not for? , 2003, The Journal of pathology.
[6] A. Giatromanolaki,et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis , 2003, British Journal of Cancer.
[7] A. Harris,et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer , 2003, The Journal of pathology.
[8] A. Harris,et al. Hypoxia‐induced pathways in breast cancer , 2002, Microscopy research and technique.
[9] Y. Taniyama,et al. Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. , 2002, Diabetes.
[10] P. Pedersen,et al. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. , 2002, Cancer research.
[11] G. Yancopoulos,et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. , 2002, Microvascular research.
[12] C. Simopoulos,et al. Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] A. Harris,et al. Angiogenic co‐operation of VEGF and stromal cell TP in endometrial carcinomas , 2002, The Journal of pathology.
[14] C. Simopoulos,et al. Prognostic Role of Angiogenesis in Operable Carcinoma of the Gallbladder , 2002, American journal of clinical oncology.
[15] D. Tsiftsis,et al. The role of 99mTc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions , 2001, Nuclear medicine communications.
[16] M. Koukourakis. Tumour angiogenesis and response to radiotherapy. , 2001, Anticancer research.
[17] D. Bouchier-Hayes,et al. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells , 2001, British Journal of Cancer.
[18] I. Zachary. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. , 2001, American journal of physiology. Cell physiology.
[19] N. Savaraj,et al. Hypersensitization of tumor cells to glycolytic inhibitors. , 2001, Biochemistry.
[20] W. Sessa,et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. , 2001, The American journal of pathology.
[21] P Vaupel,et al. Biological consequences of tumor hypoxia. , 2001, Seminars in oncology.
[22] W. Thompson. Tumour versus patient: vascular and tumour survival versus prognosis. , 2001, The Journal of pathology.
[23] R. D. de Waal,et al. Lymphangiogenesis in malignant tumours: does it occur? , 2001, The Journal of pathology.
[24] A. Harris,et al. ‘Invading edge vs. inner’ (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non‐small cell lung cancer , 2000, The Journal of pathology.
[25] A. Giatromanolaki,et al. Cancer vascularization: implications in radiotherapy? , 2000, International journal of radiation oncology, biology, physics.
[26] H. Nishimatsu,et al. Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. , 2000, Hypertension.
[27] A. Harris,et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.
[28] K. Hörmann,et al. Expression of basic fibroblast growth factor protein and its down‐regulation by interferons in head and neck cancer , 2000, Head & neck.
[29] A. Giatromanolaki,et al. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] G. Lapin,et al. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. , 1999, Microvascular research.
[31] A. Harris,et al. Combined role of tumor angiogenesis, bcl‐2, and p53 expression in the prognosis of patients with colorectal carcinoma , 1999, Cancer.
[32] A. Harris,et al. Thymidine phosphorylase expression in endometrial carcinomas , 1999, Clinical & Experimental Metastasis.
[33] A. Harris,et al. Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer , 1999, International journal of cancer.
[34] J. Martin,et al. VEGF modulates NO production: the basis of a cytoprotective effect? , 1999, Cardiovascular research.
[35] A. Giatromanolaki,et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] A. Miodoński,et al. Vascular architecture of human urinary bladder carcinoma: a SEM study of corrosion casts , 1998, Virchows Archiv.
[37] R. Brekken,et al. Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.
[38] R. Shivers,et al. Quantitative comparison of the morphology of the microvasculature of primary lung lesions and metastatic brain tumours. , 1998, Journal of submicroscopic cytology and pathology.
[39] C. Dang,et al. A unique glucose-dependent apoptotic pathway induced by c-Myc. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] K. O'Byrne,et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. , 1997, British Journal of Cancer.
[41] L. Ellis,et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. , 1996, Journal of the National Cancer Institute.
[42] S. Fox,et al. TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.
[43] A. Harris,et al. PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON‐SMALL CELL LUNG CANCER , 1996, The Journal of pathology.
[44] M. Toi,et al. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] A. Harris,et al. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] R. Whyte,et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma , 1994, The Journal of experimental medicine.
[47] R Bicknell,et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.
[48] F Pozza,et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.
[49] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.
[50] W. Thompson,et al. Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth , 1987, The Journal of pathology.
[51] R. Jain. Transport of Macromolecules In Tumor Microcirculation , 1985, Biotechnology progress.
[52] J. Vane,et al. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. , 1978, Prostaglandins.
[53] F. Cajone,et al. Anaerobic glycolysis and patterns of glycolytic intermediates during liver carcinogenesis and in hepatoma. , 1970, Journal of the National Cancer Institute.
[54] A. Harris,et al. Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer , 2004, Clinical & Experimental Metastasis.
[55] M. Toi,et al. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression , 2004, Breast Cancer Research and Treatment.
[56] Rakesh K. Jain,et al. Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.
[57] G. Semenza,et al. 'The metabolism of tumours': 70 years later. , 2001, Novartis Foundation symposium.
[58] A. Giatromanolaki,et al. Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. , 2000, Oncology research.
[59] A. Giatromanolaki,et al. Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas? , 1999, Oncology research.